FDA Allows Phase II-B Clinical Trial to Proceed Using Ischemic-Tolerant Mesenchymal Stem Cells to Treat Patients Suffering from Long-COVID
SONOMA, Calif. (PRWEB) October 20, 2022 -- Pulthera, LLC has received notice from the U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)
Source: prweb.com